Eisai launches new digital business company for dementia
Theoria technologies aims to empower those affected by dementia
Read More
Tag: Eisai
Eisai makes lecanemab therapy application
Treatment involves early Alzheimer’s disease and will be potentially used across Great Britain
Read More
Eisai and Biogen present promising lecanemab study results
Phase 3 research shows that Alzheimer’s disease treatment meets primary and secondary endpoints
Read More
Eisai’s Lecanemab phase 3 study meets primary endpoint
Results show reduction of clinical decline in global study of people with Alzheimer’s Disease
Read More
Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda
NICE approval is for first-line treatment of intermediate and advanced renal cell carcinoma
Read More
FDA approves Keytruda plus Lenvima for advanced kidney cancer
Combination treatment reduced the risk of disease progression or death by 61% versus Sutent
Read More
Lecanemab wins breakthrough therapy designation in Alzheimer’s disease
Designation is based on data from a Phase IIb study including 856 patients with mild Alzheimer’s disease
Read More
Biogen, Eisai’s Alzheimer’s drug aducanumab makes history with US approval
First new treatment approved for Alzheimer’s disease in over a decade
Read More
Eisai enters collaboration agreement with Wren Therapeutics
Companies will aim to advance drug discovery for synucleinopathies
Read More
Uni of Dundee, Eisai join forces for cancer drug discovery
The collaboration research agreement regards Proteolysis Targeting Chimeras, or PROTACs.
Read More
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read More
Eisai, Biogen move Alzheimer’s treatment into Phase III
Eisai and Biogen’s BAN2401 is to be put into Phase III trial for patients with early Alzheimer’s disease.
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
